Dr Hélène Jousset Sabroux

Dr Hélène Jousset Sabroux



Hélène Jousset Sabroux


Jousset Sabroux

Msc Compiègne PhD Geneva

Head of Screening Laboratory

I lead the Institute’s screening laboratory, which aims to discover potential new molecular scaffolds that can be developed to become new medications. We do this by testing and evaluating small molecules in biochemical or cell based assays.

We collaborate with researchers, providing screening support and expertise. We offer state-of-the-art equipment that enhances the scope and speed of experiments. 

The ultimate goal of the screening laboratory is to expedite high value research projects through access to screening technologies.

Research interest

The screening laboratory offers a wide range of expertise gained from both industrial and academic backgrounds, resulting in a professional ability to develop high capacity cellular or biochemical assays. We offer liquid handling robotics, plate readers and computing programs to increase the scale and speed of assays, and leverage automation to quickly assess the activity of a large number of compounds.

Screening technologies are highly valuable for various medical research objectives ranging from disease understanding, pathway investigation, and target identification to drug discovery.

At the start of a new collaboration, we work with researchers to develop a screening plan that can includes:

  • Assay development or assay transfer

  • Pilot screen

  • Full screen

  • Counterscreen

  • Confirmation screen

  • Hit compound dose response

  • Selectivity screen

During each and every screening step, we aim to stay in close collaboration with our collaborator and provide screening reports including detailed protocols and data analysis.

For chemical screening, the Institute owns a unique library of approximately 110,000 diverse “lead-like” chemical small molecules plus other smaller focus libraries such as kinase, epigenetic, targeted agents and known drugs libraries. Moreover, our expertise and instrumentation could also facilitate the testing of non chemical reactive agents including antibody screens and genetic screens.

Researchers and Health Minister with robotic equipment

The Australian Government has committed to $25 million in funding to enhance drug discovery capabilities at the Institute’s Drug Discovery Centre.